secwatch.observer — SEC 8-K summary
======================================

Issuer:     HYPERION DEFI, INC. (HYPD)
CIK:        0001682639
Form:       8-K
Filed at:   2024-11-15T23:59:59+00:00
Accession:  0001104659-24-119760
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eyenovia Phase 3 CHAPERONE myopia trial fails; cuts 50% staff, explores strategic options
--------------------------------------------------------------------------------

- Independent DRC found CHAPERONE not meeting primary endpoint of <0.5 diopter progression over 3 years; study terminated.
- 252 evaluable patients; no significant difference between active arms (0.01% and 0.1% atropine) and placebo.
- Workforce reduction of ~50% with $0.2M severance; remaining staff focused on Optejet Gen-2, dry eye collaborations, clobetasol.
- Company evaluating strategic options: business combination, reverse merger, or asset sales.
- Safety profile acceptable; mild and infrequent adverse events across all doses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682639/000110465924119760/0001104659-24-119760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682639/000110465924119760/tm2428238d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-119760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer